1-(1'-Methyl-1,4'-bipiperidin-4-yl)methanamine | 883533-01-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(1'-Methyl-1,4'-bipiperidin-4-yl)methanamine
• 英文别名: [1-(1-methylpiperidin-4-yl)piperidin-4-yl]methanamine
• CAS: 883533-01-5
• 化学式: C₁₂H₂₅N₃
• mdl: MFCD13857381
• 分子量: 211.35
• InChiKey: ADFNFTLPQOJDDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

文献信息

• Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs)
  申请人：Dong-A Socio Holdings Co., Ltd.

  公开号：US20160122343A1

  公开（公告）日：2016-05-05

  The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.

  本发明提供了一种式（I）的化合物，该化合物能够调节组蛋白赖氨酸去甲基化酶（KDM）的活性，以及其制备的药物组合物、制备所述化合物的方法，以及将这种化合物用作药物的用途。式（I）的化合物作为KDM抑制剂具有显著的效力，因此具有卓越的潜力用于药物干预癌症和与KDM失调相关的任何其他疾病。
• HETERO RING COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP2604601A1

  公开（公告）日：2013-06-19

  [Problem] A novel and excellent compound which is useful as an agent for preventing and/or treating rejection reactions in various organ transplantations, allergy diseases, autoimmune diseases, and hematologic tumor, and based on a PI3Kδ selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action). [Means for Solution] The present inventors have investigated a compound having a PI3Kδ selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action), and have found that the heterocyclic compound of the present invention has a PI3Kδ selective inhibitory action and/or and IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action), thereby completing the present invention.

  问题 一种新型优良化合物，可作为预防和/或治疗各种器官移植、过敏性疾病、自身免疫性疾病和血液肿瘤中排异反应的药物，该化合物基于PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括活化抑制作用）。 [解决方法］ 本发明人研究了一种具有PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括活化抑制作用）的化合物，发现本发明的杂环化合物具有PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括活化抑制作用），从而完成了本发明。
• NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS)
  申请人：Dong-A ST Co., Ltd.

  公开号：EP3212647A2

  公开（公告）日：2017-09-06
• US9834550B2
  申请人：——

  公开号：US9834550B2

  公开（公告）日：2017-12-05
• [EN] NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS)<br/>[FR] NOUVEAUX COMPOSÉS DE PYRIDOPYRIMIDINONE POUR MODULER L'ACTIVITÉ CATALYTIQUE DES HISTONE LYSINE DÉMÉTHYLASES (KDM)
  申请人：DONG A SOCIO HOLDINGS CO LTD

  公开号：WO2016068580A2

  公开（公告）日：2016-05-06

  The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.